Dyadic

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Jeudi, mars 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Retrieved on: 
Jeudi, mars 21, 2024
Transferrin, Biotechnology, Partnership, Business development, Dyadic, Food, San Francisco Marriott Marquis, Medium (website), Future, Vaccine

Dyadic will be showcasing its Dapibus™ Microbial Expression System and providing updates on the progress of current products under development within its alternative proteins business unit.

Key Points: 
  • Dyadic will be showcasing its Dapibus™ Microbial Expression System and providing updates on the progress of current products under development within its alternative proteins business unit.
  • We believe this system holds promise for revolutionizing protein expression and production in various industries, including food, nutrition, and healthcare.
  • Moreover, Dyadic has recently entered into a co-marketing partnership with Biftek, Inc. (“Biftek”).
  • If you would like to schedule a meeting with our management members at Future Food Tech in San Francisco, please contact Heidi Zosiak at [email protected] or stop by the Dyadic International, Inc. booth (#20).

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Retrieved on: 
Mercredi, février 28, 2024
Incidence, Virology, LMIC, Vaccine, C1, SME, European, Dyadic, COVID-19, Innovation, Rabies, AVATAR, Disease, DRS, Research, Partnership

The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.

Key Points: 
  • The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
  • This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.
  • As per the strategic partnership agreement, Dyadic will receive an equity stake in, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
  • Punt highlighted the potential of combining advances in vaccinology with Dyadic's C1 protein production platform to accelerate research, enhance product development, and lower manufacturing costs.

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Retrieved on: 
Vendredi, février 23, 2024
Biology, Pandemic, Vaccine, Antibody, Bacteria, Dyadic, Virus, Antigen, Patient, Partnership

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.

Key Points: 
  • JUPITER, Fla. and NES-ZIONA, Israel, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.
  • Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR.
  • Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic.
  • Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats.

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Retrieved on: 
Mercredi, février 21, 2024
Biology, Pandemic, Vaccine, Antibody, Bacteria, Dyadic, Virus, Antigen, Patient, Partnership

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.

Key Points: 
  • JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions.
  • Mark Emalfarb, Dyadic’s CEO, expressed excitement about advancing the collaboration with the IIBR.
  • Baruch Shahar, the general manager of LSRI, emphasized the collaborative history with Dyadic, which began in January 2018 and expanded during the pandemic.
  • Mr. Shahar highlighted their satisfaction with ongoing work using Dyadic's C1 technology to co-develop vaccines and treatments targeting biological outbreaks, including pandemics and other threats.

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Retrieved on: 
Mardi, février 6, 2024
C1, Traction, A-DNA, Global health, Dyadic, Research, Antibody, Vaccine

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform.

Key Points: 
  • JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform.
  • Under the agreement, research and development activities will be funded by the collaborator.
  • “Dyadic's C1 protein expression platform is gaining increased traction in research and development targeting infectious and other diseases,” said CEO Mark Emalfarb, "We are glad to see the progress of our C1-cell protein production platform for human and animal biopharmaceuticals and we believe the recent positive Phase I first in human data for a recombinant vaccine produced using C1 will spark further interest in the adoption of Dyadic’s C1 technology.”
    Dyadic is committed to enabling its partners and collaborators in the development of effective preventative and therapeutic treatments globally.
  • Dyadic is increasing global outreach to fulfill its mission to make a difference in global health by building an active pipeline through advancing its proprietary microbial platform technologies to create needed products such as recombinant human and bovine albumin and other biologic vaccines, antibodies, and products.

Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Retrieved on: 
Lundi, novembre 20, 2023
Failure, Dyadic, Vaccine, Health, Human, Animal, COVID, COVID-19, Cancer, HIV, Therapy, Pharmaceutical industry

The quest to produce affordable vaccines suited to humans and animals in Africa has taken a step closer to realization with the signing of the agreement between Rubic and Afreximaxbank.

Key Points: 
  • The quest to produce affordable vaccines suited to humans and animals in Africa has taken a step closer to realization with the signing of the agreement between Rubic and Afreximaxbank.
  • Dyadic retains the right to commercialize human and animal health vaccines and therapeutics developed by Rubic outside of the African continent.
  • We realized early in the COVID-19 pandemic that there is significant vaccine inequity in Africa, and that we are at the mercy of big pharma and developed countries.
  • This is a game changer in the vaccine manufacturing space for the African people,” concluded Dr. Naidoo.

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Mercredi, novembre 8, 2023
Massachusetts General Hospital, VIC, Research, Insurance, Health, Infection, Vaccine, Enzyme, RNA, Department of Defense Serum Repository, Business development, Biofuel, Livestock, Protein, Filoviridae, EDCL, MHCII, Clinical trial, COVID-19, Webcast, Department of Defence, Business, Messenger, SAS, Animal, Phibro, Safety, Negotiation, Microsoft, Hospital, D, Cryptocurrency, Fine chemical, Pharmaceutical industry, Life insurance, C1, Dyadic

Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.

Key Points: 
  • Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.
  • Interim phase 1 clinical trial safety results are helping to accelerate the adoption of our C1 protein production platform in use for manufacturing human vaccines.
  • In October 2023, the Company received an upfront payment of $0.6 million for product development.
  • The Company is making progress in developing animal-free recombinant serum albumin with initial positive analytical results towards commercialization and prospective licensing opportunities.

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacc

Retrieved on: 
Jeudi, octobre 5, 2023
Infection, Lipid, U.S. Department of Defense Strategy for Operating in Cyberspace, SAV, Dyadic, Safety, Massachusetts General Hospital, C1, Hospital, Therapy, VIC, Protein, Antigen, Research, Vaccine, Voltron

This research collaboration resulted from a $5.88 million award that VIC received from the U.S. Department of Defense (“DoD”).

Key Points: 
  • This research collaboration resulted from a $5.88 million award that VIC received from the U.S. Department of Defense (“DoD”).
  • The award is intended to be used to advance the development of a Self-Assembling Vaccine (“SAV”) Platform for rapid production of prophylactic vaccines for various infectious diseases.
  • SAVs have demonstrated the potential to cause more efficacious immune response and protection, which provides a promising strategy for vaccine construction.
  • We anticipate that this work will help create a valuable infectious disease pipeline as well as contribute to our Immuno-Oncology programs.”

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

Retrieved on: 
Mardi, septembre 26, 2023
Therapy, C1, COVID-19, RNA, USD, Messenger, SAS, Patient, Health, Vaccine, Dyadic

JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA ("mRNA").

Key Points: 
  • JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA ("mRNA").
  • bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.
  • “If this collaboration is successful, Dyadic has the potential to receive certain defined milestone and royalty payments from bYoRNA and the ability to obtain a license to the BRNA platform,” Mr. Emalfarb concluded.
  • “The COVID-19 pandemic brought mRNA technology to the forefront, showing its potential to prevent and treat diseases.